184 related articles for article (PubMed ID: 34879849)
1. Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer.
Schnepp PM; Ahmed A; Escara-Wilke J; Dai J; Shelley G; Keller J; Mizokami A; Keller ET
BMC Cancer; 2021 Dec; 21(1):1316. PubMed ID: 34879849
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells.
Schnepp PM; Shelley G; Dai J; Wakim N; Jiang H; Mizokami A; Keller ET
Mol Cancer Res; 2020 Sep; 18(9):1290-1301. PubMed ID: 32513898
[TBL] [Abstract][Full Text] [Related]
3. Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.
Xu Q; Liu X; Zhu S; Hu X; Niu H; Zhang X; Zhu D; Nesa EU; Tian K; Yuan H
J Cell Mol Med; 2018 Mar; 22(3):1909-1922. PubMed ID: 29327812
[TBL] [Abstract][Full Text] [Related]
4. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
5. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
[TBL] [Abstract][Full Text] [Related]
6. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
9. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
10. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
12. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway.
Sun X; Zhang Y; Xin S; Jin L; Cao Q; Wang H; Wang K; Liu X; Tang C; Li W; Li Z; Wen X; Yang G; Guo C; Liu Z; Ye L
Cancer Sci; 2024 Feb; 115(2):412-426. PubMed ID: 38115797
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Nalairndran G; Chung I; Abdul Razack AH; Chung FF; Hii LW; Lim WM; Looi CK; Mai CW; Leong CO
J Cell Mol Med; 2021 Sep; 25(17):8187-8200. PubMed ID: 34322995
[TBL] [Abstract][Full Text] [Related]
15. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Puhr M; Hoefer J; Neuwirt H; Eder IE; Kern J; Schäfer G; Geley S; Heidegger I; Klocker H; Culig Z
Oncotarget; 2014 Dec; 5(23):12043-56. PubMed ID: 25474038
[TBL] [Abstract][Full Text] [Related]
16. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
Gruber M; Handle F; Culig Z
Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
Feng Q; He P; Wang Y
Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
[TBL] [Abstract][Full Text] [Related]
18. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
19. Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer.
Qian S; Zhang S; Wu Y; Ding Y; ; Li X
Chemotherapy; 2020; 65(5-6):125-133. PubMed ID: 33238278
[TBL] [Abstract][Full Text] [Related]
20. Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer.
Liu RJ; Li SY; Liu LQ; Xu B; Chen M
Bioengineered; 2021 Dec; 12(1):2377-2388. PubMed ID: 34077304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
